NOS1 and melanoma: Given the potential gastrointestinal adverse effects associated with nNOS inhibition, our strategy aims to blend targeted therapy (nNOS inhibitors) with targeted delivery, by coupling the small molecule with KK-11 to optimize the anti-melanoma treatment.